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Abstract
Point-of-care (POC) testing has proven to be a life-changing and transformational 
technology for patients with acute, chronic, and infectious diseases who live in 
regional and remote Australia. This technology facilitates patient-centred test results, 
of equivalent laboratory quality, that are rapidly available to inform clinical and 
public health decisions with immediate impact on case management. Traditionally, 
POC testing in high-middle income countries has been most widely used in tertiary 
or acute care settings to provide rapid diagnostic results for emergency departments, 
intensive care units, operating theatres and outpatient clinics. However, in low-mid-
dle income countries, POC tests are commonly used during antenatal and perinatal 
care for infectious disease detection, such as Human immunodeficiency virus (HIV) 
or syphilis, where laboratory services are too expensive, inaccessible, or non-existent. 
Similarly, the application of POC testing in primary care settings in Australia offers 
improved healthcare benefits to geographically isolated regional and remote com-
munities, where access to laboratory-based pathology testing is poor and the burden 
of disease is high. Evidence-based data from research in established primary care 
POC testing networks for acute chronic, and infectious disease is used to describe the 
clinical, cultural, and economic effectiveness of POC technologies. Innovative solu-
tions to address current barriers to the uptake of POC testing in primary care settings, 
which include clinical and cultural governance, high staff turnover, operator training 
and competency, device connectivity, quality testing, sustainable funding strategies, 
and the need for regulatory requirements are also discussed. POC testing can provide 
practical and resourceful opportunities to revolutionise the delivery of pathology 
services in rural and remote primary care sectors, where the clinical and community 
need for this technology is greatest. However, several barriers to the scale-up and sus-
tainability of POC testing networks in these settings still exist, and the full potential 
of POC testing cannot be realised until these limitations are addressed and resolved.
Keywords: Primary health care, point-of-care testing, patient-centred care, remote, 
Australia
1. Introduction
Primary health care describes the first contact an individual with a health 
concern has with the health system that is not related to a hospital visit. This may 
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include health promotion, prevention, early intervention, treatment of acute condi-
tions, and management of chronic conditions or infectious disease [1].
In 2015–2016, the proportion of the Australian health budget spent on primary 
health care (approximately 35%, representing approximately $AUS 59 billion) was 
similar to that of country’s hospital services (39%, representing approximately 
$AUS 66 billion), reflecting the vast and diverse geographical and cultural require-
ments for health care services in the country [2]. In rural and remote Australia, 
healthcare services in primary care differ to that in urban or metropolitan areas. 
Primary healthcare facilities are generally small, with less infrastructure to provide 
a broad range of health services to a wide geographically distributed population 
[3]. In addition to a lack of resources, the health of those living in rural and remote 
Australian locations is also poorer, with the life expectancy for both males and 
females decreasing with increasing remoteness [3]. The workforce of Australian 
rural and remote primary health care relies more on general practitioners (GPs) 
to provide health care services, either on-site, or more recently via telehealth 
consultations [4, 5]. The remote primary healthcare sector is also largely supported 
by nurses and Aboriginal Health Practitioners [6]. Due to the high proportion of 
Aboriginal and Torres Strait Islander people living in remote Australia, health ser-
vices in these regions are provided by either: (i) Aboriginal Community Controlled 
Health Services (ACCHOS), which are funded by the Australian Government and 
administered by a Board comprising Aboriginal and Torres Strait Islander repre-
sentatives from the respective community or (ii) State or Territory funded health 
services [7]. With the burden of acute, chronic, and infectious diseases amongst 
Aboriginal and Torres Strait Islander people higher than that of the non-Indigenous 
population and the highest Indigenous disease rates correlating with degree of 
geographic remoteness [3], the overarching Indigenous governance of ACCHOs 
assists in the delivery of culturally safe health services to address health inequity in 
Australia [7].
Point-of-care (POC) testing refers to pathology testing performed in a clinical 
setting at the time of patient consultation, generating a rapid test result that enables 
timely clinical decision making for patient care [8]. POC testing has proven to be 
a transformative and life-changing technology for health services and patients 
in remote Australian communities. From the patient perspective, POC testing 
provides a convenient and accessible ‘one-stop’ health service. In this context, POC 
testing empowers the patient to be accountable for their own health, eliminating 
the need for multiple follow-up visits to the health services to access diagnostic 
test results and commence treatment or other interventions. It is also assumed that 
POC testing reduces patient anxiety associated with waiting for pathology results 
as test results can be obtained quickly and discussion with the treating clinician 
can commence immediately. From a clinical perspective, POC test results allow the 
health practitioner to make immediate and informed decisions for patient manage-
ment, including the rapid initiation of treatment and/or alternative health interven-
tion strategies. From a cultural perspective, POC testing has enabled Aboriginal 
and Torres Strait Islander people without life-threatening conditions to be safety 
monitored and/or treated in their own community [9]. Thus, POC testing not only 
averts costly medical evacuations, but also allows First Nation people to remain 
on ‘Country’ with community and cultural support during the recovery period. 
Additionally, POC testing assists remote communities by building local health 
workforce capacity and facilitating an extended scope of practice for Aboriginal 
Health Practitioners, who can be trained to conduct POC testing. In qualitative sur-
veys, Aboriginal Health Practitioners reported being trained and competent in POC 
testing as “empowering them to care for patients in their local communities” [10].
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2. Examples of primary care POC testing networks in Australia
The Flinders University International Centre for Point-of-Care Testing 
(ICPOCT) is a specialist POC test provider, with over 20 years of experience in 
the establishment, management, and evaluation of best-practice POC testing to 
improve access to routine pathology services. At present, the ICPOCT indepen-
dently manages five POC testing networks and is a collaborating partner with 
the Kirby Institute at the University of New South Wales (UNSW) on a further 
two POC testing networks. Table 1 summarises the ICPOCT and collaborative 
partnership POC testing programs indicating the POC test device used, the POC 
test/s performed, the time taken to generate the POC test result, and the number of 
participating health clinics. The complexity of the POC methodologies and device 
types used across these POC testing programs ranges from simple, lateral flow 
rapid antibody tests with qualitative results (e.g. used to detect Treponema pallidum 
(Syphilis) infection) to complex, gold-standard, nucleic acid amplification tests 
(NAATs) which utilise safe, closed cartridge test systems for the qualitative detec-
tion of infectious disease RNA (e.g. used to diagnose SARS-CoV-2 (COVID-19)  
infection) or DNA (e.g. used to detect Chlamydia trachomatis (Chlamydia),  
Neisseria gonorrhoeae (Gonorrhoea) and Trichomonas vaginalis (Trichomonas) 
infections) or the quantitative detection of infectious disease RNA viral load  












QAAMS Siemens DCA HbA1c^ 7 min 238
Vantage Urine ACR# 6 min
NT i-STAT Abbott i-STAT Electrolytes (sodium and 
potassium), glucose, Hb~, urea, 
creatinine, Cardiac troponin I Blood 














Chlamydia, Gonorrhoea and 
Trichomonas
60–90 min 55
ESR Abbott Syphilis 
TP
Syphilis 15 min 84








Total WBC count plus five-part 
differential
5 min 20
^Haemoglobin A1c, #albumin:creatinine ratio, ~Haemoglobin, *International Normalised Ratio, +Severe Acute 
Respiratory Syndrome Coronavirus 2, **Partnership POC testing program with the Kirby Institute, University of 
New South Wales.
Table 1. 
Summary of primary care POC testing networks managed by the ICPOCT (Flinders University) alone, or in 
collaborative partnership with the Kirby Institute (UNSW).
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The POC testing programs described in Table 1 are primarily focussed in rural 
and remote Australian primary care settings, with the general location of health 
services participating in the seven networks represented in the series of maps 
in Figure 1(A–F). Indicative of the clinical need for diagnostic test provision by 
POC testing, it is notable that over 50% of the health services participating in the 
Aboriginal and Torres Strait Islander COVID-19 POC testing program are located 
more than 10 hours’ drive from a laboratory testing facility and thus complement 
laboratory services [11]. In addition, primary health care services particularly in 
the most remote parts of Australia (notably the Northern Territory and north-west 
and central Western Australia) actively participate concurrently in up to six POC 
testing networks so that they can facilitate a broad range of on-site diagnostic tests 
for patient centred-care (Figure 2).
The Quality Assurance in Aboriginal Medical Services (QAAMS) POC testing 
program for diagnosis and management of diabetes and renal disease, the Aboriginal 
and Torres Strait Islander COVID-19 (COVID-19) POC testing program, the Test, 
Treat ANd GO (TTANGO) POC testing program for sexually transmitted disease 
Figure 1. 
(A–C). Point-of-care testing network maps under the jurisdiction of the ICPOCT. (D–F). Point-of-care testing 
network maps under the jurisdiction of the ICPOCT.
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diagnosis and monitoring and the Enhanced Syphilis Response (ESR) POC testing 
program are all funded by the Australian Government and thus include site selec-
tion criteria for national testing coverage, complementary to regional and urban 
laboratories. The COVID-19 and ESR POC testing programs were both established 
as ‘emergency response’ initiatives under the directive of the Australian Government 
[12]. The Northern Territory (NT) i-STAT POC testing program for acute disease 
management (blood gas, urea/electrolytes and cardiac troponin I), and Prothrombin 
(PT)/International Normalised Ratio (INR) monitoring and the White Blood Cell 
(WBC) Differential (DIFF) POC testing program for sepsis diagnosis are both funded 
by the NT Government Department of Health and include site selection criteria and 
enrolled health services specific to the remote Central and Top End regions of the NT. 
Similar to the NT funded POC program, the Western Australian (WA) Syphilis POC 
testing program is a state-based network funded by the WA Government Department 
of Health, facilitating syphilis POC testing in broad range of decentralised setting 
including: remote, regional, and urban community services, hospital maternity wards, 
peer harm reduction outreach services, homeless health care services and prisons.
The QAAMS Program has been operational for 22 years [13], and is economically 
sustainable at the health service level due to the availability of specific public health 
(Medicare Benefits Schedule (MBS)) rebates for: (i) glycated haemoglobin A1c 
(HbA1c) POC testing for diabetes diagnosis or management and (ii) urine albumin 
to creatinine ratio (UACR) POC testing for monitoring of renal disease, when the 
quality management is compliant under the auspices of the QAAMS program. At 
present, the QAAMS program supports the only POC testing performed outside 
of an accredited laboratory facility within Australia to have approved MBS item 
numbers. Dependant on regulatory system development to facilitate accredita-
tion processes, an equivalent MBS rebate may soon expand to HbA1c POC testing 
performed independently within GP clinics in Australia.
Like the QAAMS program, the NT i-STAT POC testing also has significant 
longevity, with 13 years of continuous operation and government funding [14]. 
The sustainability of the NT i-STAT POC testing program is largely associated with 
the demonstrated economic benefits of POC testing in acute clinical management 
in remote primary health care, due to averted medical evacuations [15]. The NT 
Figure 2. 
Merged ICPOCT point-of-care network maps.
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government has also recently expanded the NT POC testing network to facilitate 
twenty total white blood cell (WBC) count POC devices (HemoCue, Radiometer) 
with 5-part WBC differential for sepsis management in the Top End NT sites.
The COVID-19 and TTANGO POC testing programs, and more broadly a National 
Health and Medical Research Council (NHMRC) Centre for Research Excellence for 
Infectious Disease POC Testing in the Asia-Pacific, are representative of a long-term, 
collaborative partnership between the ICPOCT and the Kirby Institute (UNSW). 
The COVID-19 and TTANGO POC networks use gold-standard NAATs within a safe, 
closed cartridge testing system to detect the respective infectious disease RNA or 
DNA, using the Cepheid GeneXpert POC device [11]. Some POC devices, including 
the GeneXpert (Cepheid), offer broad clinical application with extensive test menus 
as well as the rapid development of newer in vitro diagnostic tests utilising the same 
test cartridge design and device infrastructure. Utilising this capability, a new col-
laborative POC testing network (with the Kirby Institute) for capillary (fingerstick) 
hepatitis C viral load using the GeneXpert will be established in late 2021 to early 
2022. Funded by the Australian Government, the National Hepatitis C (HCV) POC 
testing program, will focus on the application of a Class IV in vitro diagnostic POC 
test in a broader range of primary care settings. Justice health services, safe drug injec-
tion rooms, community needle and syringe programs and homeless health services 
will be eligible as high prevalence, decentralised test sites for enrolment into the 
National HCV POC testing program. The overall aim of the National HCV POC test-
ing program is to support Australia’s contribution to the World Health Organization’s 
global goal to eliminate hepatitis as a public health threat by 2030 [16]. In addition, 
future infectious disease research to investigate the potential advantages of using 
multiplexed POC test cartridges, such as respiratory panel, including Influenza A, 
Influenza B (Flu A/B), COVID-19 and Respiratory Syncytial Virus (RSV) in primary 
care settings using the GeneXpert in Australia may also be warranted.
3. Clinical outcomes
In the Australian primary care POC testing programs described above, the 
evidence-based clinical outcomes that benefit patient care following the introduc-





POC test Outcome measure
QAAMS Chronic HbA1c^ Improvement in glycaemic control
NT i-STAT Acute Cardiac Troponin I Early risk stratification for acute coronary 
syndrome
Potassium Stabilisation of patients with severe vomiting 
or diarrhoea
Chronic INR* Improved time in therapeutic range
NT WBC 
DIFF
Acute White blood cell 
count
Assisted with patient triage
TTANGO Infectious Chlamydia and 
Gonorrhoea
Reduction in time to treat
COVID-19 Infectious SARS-CoV-2+ Early detection/reduced time to treat
^Haemoglobin A1c, *International Normalised Ratio, +Severe Acute Respiratory Syndrome Coronavirus 2.
Table 2. 
Summary of key clinical outcome measures from Australian primary care POC testing networks.
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Briefly, some of these benefits include: (i) improved glycaemic control in patients 
with type 2 diabetes [17], (ii) improved time in therapeutic range for warfarin-
treated patients [18], (iii) early risk stratification for acute coronary syndrome [19], 
(iv) assisted triaging and determination of need for medical evacuation in septic 
patients with four different medical presentations and [20] (v) reduced time to 
treat sexually transmitted disease [21, 22]. These positive clinical outcomes associ-
ated with the introduction of POC testing in remote primary health care services 
highlight some of the life-changing impact that this type of technology can offer in 
decentralised patient care settings.
4. Patient-centred outcomes
POC testing enables the patient to be at the centre of healthcare processes. 
Diagnostic POC test results are rapidly available within the initial on-site con-
sultation, inform prompt patient management decisions and even may fast-track 
additional clinical investigations, as required. For the patient, this eliminates the 
need to attend separate phlebotomy collection services and return for a follow-up 
visit to discuss laboratory test results, thus making POC testing patient-centric and 
linkage to care convenient. Other cited patient benefits for POC testing include: (i) 
increased adherence to diabetes medication [23], (ii) reduced pain and/or anxiety 
associated with capillary, rather than venous blood collection, particularly for elderly 
or paediatric patients, and (iii) an increased likelihood of patients consenting to 
diagnostic testing [24]. Furthermore, the wait for the return of diagnostic test results 
is a reported cause of anxiety [25, 26], so in this context, POC testing may also reduce 
overall patient anxiety or stress related to waiting for laboratory test results [27].
In acute care settings, POC testing changes lives, with rapid results informing 
prompt diagnosis and rapid initiation of patient stabilisation and/or treatment. An 
example is the use of i-STAT cardiac troponin I POC testing within the NT POCT 
Program for the immediate diagnosis of non-ST elevation myocardial infarction 
(non-STEMI) in remote patients [19]. In this scenario, if cardiac troponin I POC test-
ing was not available, non-STEMI events may not be quickly diagnosed and treated 
[19]. Without POC testing, remote patients who often miss scheduled dialysis due 
to cultural and community obligations may also become acutely ill. In these cases, 
the i-STAT POC device can be used to detect critical levels of hyperkalaemia, so that 
immediate treatment with calcium gluconate to lower cardiac risk can be initiated 
[19]. In dehydrated patients, with acute vomiting or diarrhoea, i-STAT POC testing 
facilitates frequent monitoring of the patient’s electrolyte levels during stabilisation 
with IV or oral fluid administration [19]. In these remote primary care settings, POC 
testing facilitates information to avert the time, inconvenience and cost of unneces-
sary transfer to a tertiary medical facility. Averting unnecessary medical evacuations 
can be particularly significant for Aboriginal and Torres Strait Islander people who 
live in remote communities, where the dislocation from community and Country can 
cause significant mental distress [28, 29]. Though brief, these examples illustrate how 
POC testing can be a life-changing technology at the individual patient level, particu-
larly for those who would not otherwise be able to access timely pathology results.
5. Public health outcomes
Beyond the individual patient level, POC testing programs have the capability to 
facilitate broader public health benefits. For example, one of the site selection criteria 
for the COVID-19 POC Program was that primary health care services were located a 
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minimum of 2 hours’ drive from an existing COVID-19 testing laboratory facility and 
serviced predominately Aboriginal and Torres Strait Islander communities of greater 
than 500 people. Indicative of the clinical need of the COVID-19 POC testing program 
for remote, priority communities, by the completion of site enrolment, approximately 
half of the participating health services were located more than 10 hours’ drive from 
a laboratory testing facility and included several health services located on remote 
islands requiring dedicated flights to reach mainland COVID-19 testing services [11]. 
To provide wider COVID-19 testing access, a hub and spoke model was established, 
whereby nasopharyngeal swab samples were collected from patients in neighbouring 
spoke communities, placed into virus inactivating molecular transport media and 
transported to the hub testing sites. The hub and spoke POC testing model expanded 
total testing capability to approximately one hundred and fifty at-risk communities 
(from eighty-eight hub testing sites). With over 32,000 patient COVID-19 POC tests 
performed nationally to date, the Aboriginal and Torres Strait Islander COVID-19 POC 
testing program has significantly reduced the time required for isolation/quarantining 
for vulnerable individuals who test negative as the turn-around time for COVID-19 
results is reduced from an average three-day turn-around time for laboratory testing to 
less than one hour per test for POC testing. Applying similar assumptions of com-
munity size, remoteness and access to laboratory test facilities as those reflected in the 
site selection criteria for the COVID-19 POC testing program, mathematical modelling 
used to inform the Australian Government, indicated that by reducing the time for 
COVID-19 case identification and isolation from ten days, the COVID-19 transmission 
rate changed from that associated with an uncontrolled outbreak to a either a signifi-
cant surge or controlled condition, for reductions of five or three days, respectively 
[30]. The ability to reduce isolation and quarantining duration for negative COVID-19 
cases is particularly relevant to remote communities within Australia, where self-
isolation may be difficult due to a lack of suitable housing and/or over-crowding, or 
impacted by other social and cultural determinants [31]. Most recently, the Aboriginal 
and Torres Strait Islander COVID-19 POC testing program rapidly scaled-up the 
number of GeneXpert devices, competent staff and test cartridges available to deliver 
COVID-19 results required for case identification, contact tracing and public health 
response in emergency outbreak local government areas of New South Wales (NSW), 
as opposed to waiting several days for laboratory results [32]. In addition, in outbreak 
response areas and other under-resourced remote communities, the COVID-19 POC 
testing program has enabled mobile employees to be rapidly screened using molecular-
based COVID-19 testing. In these circumstances, POC testing has assisted with crisis 
workforce capacity, whilst also providing a level of protection to the local communities 
by minimising COVID-19 infection transmission risk.
For the TTANGO Program, a significantly improved “time to treat” sexually 
transmitted Chlamydia and Gonorrhoea infections in comparison to regular test 
processes was demonstrated by the application of rapid POC molecular-based test 
results in remote Australian communities [22]. For sexually transmitted diseases, 
prompt diagnosis and public health notification, patient education and treatment 
hasten STI contact tracing aiming to decrease the onward and/or vertical transmis-
sion of STIs in the community.
For chronic diseases, such as type 2 diabetes and the associated renal compli-
cations, the availability of POC testing provides extended scope for consented 
screening tests of at-risk populations. In these patients, POC testing facilitates link-
age to early education of the disease and lifestyle interventions that can afford the 
patient improved long-term monitoring and improvement of their long-term health 
outcomes, without a loss to follow-up [33]. Early identification and treatment 
of chronic disease, such as type 2 diabetes, that slows the progression of disease 
complications, may in turn may lead to reduced burden on tertiary care facilities.
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6. Economic outcomes
Data which demonstrates the cost effectiveness of POC testing, comparative to 
laboratory testing, is essential for ensuring the initial feasibility and sustainability 
of POC testing models worldwide. Previously, our research demonstrated savings 
of over $21 million per annum for the NT Government through averted unnecessary 
medical retrievals as a result of acute i-STAT POC test results in the remote com-
munities within the NT POCT program [15]. Similarly, economic savings have been 
reported in rural New Zealand hospitals, where an annual cost reduction of more 
than $NZ 450,000 was realised from POC testing through a decreased number of 
hospital transfers and an increase in the hospital discharge rates [34]. In the United 
Kingdom, a primary care study also reported that POC testing was cost effective, in 
comparison to laboratory testing, when used to perform routine health checks as the 
results were available at the first consultation [33]. A review of POC testing health 
economics in remote primary health care settings also provided general support 
for POC testing benefits to health services outweighing the associated costs [35]. In 
Australia, the Medical Services Advisory Committee (MSAC), is an independent, 
non-statutory committee established by the Minister for Health, that is responsible 
for the appraisal of new medical services proposed for public funding, including 
POC testing. MSAC provides advice to the Australian Government on whether 
a new medical service should be publicly funded, based on an assessment of its 
comparative safety, clinical effectiveness, cost-effectiveness, and total cost, using 
the best available evidence. Amendments and reviews of existing Medical Benefits 
Schedule (MBS) services, including POC tests, are also considered by MSAC. In this 
regard, evidence-based Australian economic cost-effectiveness data that supports 
the application of POC testing in primary care is paramount to ensure the economic 
sustainability of POC testing through public funding models.
7. Key elements of POC testing networks
Best-practice POC testing models are underpinned by a common set of core ele-
ments as illustrated in Figure 3. These include: (a) a defined clinical or public health 
need for POC testing, (b) appropriate site selection, targeting priority populations 
with high disease prevalence or risk, (c) clinical and cultural governance of the 
POC testing procedures and patient test results, (d) engagement with the com-
munity to ensure patients are educated in understanding the health benefits of POC 
testing and can be easily linked to appropriate models of healthcare, (e) robust 
training and competency assessment processes for health professionals conducting 
POC testing to minimise patient harm, (f) continuous surveillance of analytical 
quality using internal quality control and external quality assurance programs, 
with prompt and appropriate actioning to maintain satisfactory analytical quality 
standards, (g) provision of an intensive level of technical and scientific trouble-
shooting support to maximise device operation and result quality, (h) connectiv-
ity and real-time reporting systems to ensure rapid patient result transmission, 
complete patient result audit trails and allow appropriate public health notification 
of required patient infectious diseases (noting that POC connectivity systems can 
be complex to integrate and sustain in primary care settings and are not always cost-
effective) and (i) supply and logistical management of equipment, reagents and 
consumables, often to remote locations with sub-tropical or tropical climates. Once 
established, ongoing evaluation of the clinical effectiveness and utility, cultural 
effectiveness, benefits to patient and community, cost-effectiveness, risk manage-
ment assessments and limitations of each POC testing program is integral to ensure 
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continual quality process improvement. The sustainability of best-practice POC 
testing is reliant on the continual development of national and international of POC 
testing implementation and management policies and robust guidelines that arise 
from translational research of best-practice POC testing networks [36].
Whilst the POC testing models described have been implemented with finan-
cial support from Australian Commonwealth and/or State Governments, several 
challenges currently exist when considering the sustainability and viability of POC 
testing in remote locations. These are summarised in Table 3. At a local community 
level, there can be saturation of health services with POC testing network require-
ments regarding staff capacity. This is particularly evident when individual health 
services enrol in multiple POC testing programs and experience rapid staff turn-
over. For ACCHOS, Commonwealth support for targeted POC testing remote staff, 
to be managed through the national leadership body for Aboriginal Community 
Controlled Health Organisations (NACCHO) may assist in alleviating future 
workforce shortages. More broadly, feasibility studies and predictive modelling can 
be applied to remote primary care scenarios prior to implementation to ensure POC 
testing networks are scaled to maximise reach and outcome benefits. At a national 
level, the existing regulatory framework for POC testing performed outside a 
clinical laboratory setting is somewhat rudimentary, with newer POC technologies 
superseding the 2015 National Pathology Accreditation Advisory Council (NPAAC) 
Guidelines for POC testing. Broader clinical acceptance and public health funding 
of POC test results performed in decentralised Australian primary care settings is 
reliant of the development and evaluation of a formal regulatory system for best-
practice POC testing performed outside that of an accredited laboratory frame-
work. In addition, further integration of patient POC test results from primary 
Figure 3. 
Key elements of a best-practice point-of-care testing network.
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care settings into patient management systems and/or electronic medical records is 
required to overcome the current lack of accessibility of historical POC test results 
which may be useful for patient management (e.g. past history of sexually transmit-
ted diseases). It is only when the current challenges POC testing are overcome that 
the full benefits of POC testing in decentralised primary care settings can be widely 
recognised, accepted, and sustained [37].
In summary, POC testing in Australia can be considered a life-changing technol-
ogy as it can: a) provide equity of access to pathology services in remote and under-
resourced locations, b) support prompt medical evacuation and public health 
decisions c) be cost-effective, in comparison to laboratory testing or overall health 
service savings, if the network scale-up is optimised prior to implementation, and 
d) has capacity to deliver individualised patient-centred care. If the current chal-
lenges and barriers to POC testing sustainability can be further addressed, a wider 
range of clinical, public health and economic benefits could be realised through 
new and/or additional POC testing initiatives for high priority, at-risk populations, 
especially in rural and remote Australian communities.
Challenge Comment
Governance A multidisciplinary management committee, with representatives from clinical, 
scientific, nursing, Indigenous, industry, collaborative research partners and 
Government stakeholder groups, provides maximum support for the POC 
testing model
Staff Turnover There is a requirement for flexible options for training delivery to ensure 
operator competency standards are maintained in the face of high staff turnover
Devices and 
Consumables
There needs to be commitment from industry for continuity of cold-chain 
supply of cartridges and QC material to remote health services
Connectivity A cost-efficient solution for the electronic capture and transfer of pathology 
results to a patient management system is critical for network sustainability
Government funding/
support
Government support for POC testing and a reimbursement (rebate) mechanism 
for cartridge costs is essential for long-term viability of a POC testing network
Accreditation Accreditation frameworks for POC testing networks need to be flexible and 
adaptable to the many different clinical settings in which POC testing is 
undertaken
Saturation of POC 
testing uptake
When a service is engaged in multiple POC testing networks, the imposition of 
training needs and different quality management testing materials and regimes 
can impede the uptake and acceptability of POC testing, even in settings where 
significant clinical needs exist
Scalability of POC 
testing networks
Prior to implementation of POC testing, the capacity for scalability of the POC 
testing model needs to consider not just analytical quality and clinical benefits of 
POC testing but also factors such as acceptability and cost effectiveness
Table 3. 
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